Results for this period
First quarter1 January 2026 to 31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
As a result of recording research and development expenses of ¥103.293 million, compared with ¥82.038 million in the same period of the previous year, the operating loss was ¥237.327 million, the ordinary loss was ¥242.643 million, and the quarterly net loss was ¥250.576 million.
Events and conditions that may cast significant doubt on the going-concern assumption are disclosed. Although the Company has identified events or conditions arising from operating losses and other factors that may cast significant doubt, it has determined that no material uncertainty exists because the necessary funds have been secured with cash and deposits on hand.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 January 2026 to 31 March 2026 |
| Operating profit | ¥-237 million |
| Ordinary income | ¥-242 million |
| Profit attributable to owners of the parent | ¥-250 million |
| Net income per share | ¥(21.56) |
| Equity ratio | End of the current fiscal period 36.0% / End of previous period 43.1% |
| Total assets | ¥2,821 million |
| Net assets | ¥1,015 million |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit ¥-1,520 million / Ordinary income ¥-1,550 million / Net income ¥-1,616 million |
| Annual Dividend Forecast | ¥0.00 → ¥0.00（0.0%） |
| Impairment loss | ¥7,014 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Losses ¥7,014 thousand |
| Disclosure regarding the going concern assumption | Events and conditions that may cast significant doubt on the going-concern assumption are disclosed. Although the Company has identified events or conditions arising from operating losses and other factors that may cast significant doubt, it has determined that no material uncertainty exists because the necessary funds have been secured with cash and deposits on hand. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 11,622,600 shares |
| Treasury Shares at Period-End | 0 shares |
| Factors Behind Changes in Business Performance | As a result of recording research and development expenses of ¥103.293 million, compared with ¥82.038 million in the same period of the previous year, the operating loss was ¥237.327 million, the ordinary loss was ¥242.643 million, and the quarterly net loss was ¥250.576 million. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company explained that operating loss and other losses widened as a result of recording research and development expenses of ¥103.293 million, compared with ¥82.038 million in the same period of the previous year.